Compare Roundhill NVDA WeeklyPay ETF (NVDW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill NVDA WeeklyPay ETF vs Viatris Inc — how do they compare? Roundhill NVDA WeeklyPay ETF trades at $36, while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc pays a 2.83% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Viatris Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NVDW | VTRS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $53.42 | $17.39 |
52-Week Low | $31.88 | $8.74 |
Market Cap | — | $19.79B |
Enterprise Value | — | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDW trades at $35.20, down 1.1% today, with technical indicators showing bearish momentum as moving averages signal strong selling pressure. The ETF maintains an active dividend distribution schedule with multiple payouts in recent months, though key valuation metrics remain unavailable for analysis. Current price action sits near support at $35 with resistance forming at $36.
The outlook remains cautious given the bearish technical signals and lack of fundamental data transparency. Investment opportunity exists primarily through the dividend income stream, though payout volatility presents risk. Market sentiment appears mixed with Seeking Alpha highlighting the ETF's role as a Nvidia hedge with variable yield characteristics.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
